Arming "old guards" with "new dual-targeting weapons".
Arming "old guards" with "new dual-targeting weapons".
复制标题
用“新型双目标武器”武装“老卫士”。
DOI：
10.1016/j.ccell.2021.04.010
复制
发表时间：
2021
期刊：
影响因子：
50.3
通讯作者：
Tushir-Singh,Jogender
中科院分区：
文献类型：
--
作者：
Lum,LawrenceG;Tushir-Singh,Jogender
长期以来，肿瘤抑制剂在癌症治疗中是不可靶向的，这一观点受到了《科学》杂志上发表的一项研究的挑战。这项最新工作优雅地描述和表征了p53突变体肽选择性TCR模拟抗体及其共靶向T细胞活化双特异性抗体，以消除表达新抗原的肿瘤。
The long-held paradigm that tumor suppressors are un-targetable in cancer therapy is challenged by a study published inScience. This recent work elegantly describes and characterizes a p53 mutant peptide-selective TCR-mimic antibody and its co-targeting T cell-activating bispecific antibody to eliminate neoantigen-expressing tumors.